Errata

The January 10, 2015, article by Cainap et al entitled “Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial” (J Clin Oncol 33:172-179, 2015) was published with Dr Cainap’s affiliation listed incorrectly.

In the Affiliations section, **University of Medicine and Pharmacy Cluj Napoca** should have been listed as the affiliation of Calin Cainap.

The online version has been corrected in departure from the print. The authors apologize for the error.

DOI: <https://doi.org/10.1200/JCO.2017.74.5729>; published August 1, 2017

The August 1, 2015 article by Cainap et al entitled “Reply to M. Bouattour et al” (J Clin Oncol 33:2486-2486, 2015) was published with Dr. Cainap’s affiliation listed incorrectly.

In the Affiliations section, **University of Medicine and Pharmacy Cluj Napoca** should have been listed as the affiliation of Calin Cainap.

The online version has been corrected in departure from the print. The authors apologize for the error.

DOI: <https://doi.org/10.1200/JCO.2017.74.5760>; published August 1, 2017

The March 1, 2017 article by Naidoo et al entitled “Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy” (J Clin Oncol 35:709-717, 2017) was published with errors.

The manuscript should have stated that Dr. Georgina Long and Dr. Matthew Hellmann contributed equally to the manuscript.

The full name of CTLA-4 is written out incorrectly as anti-cytotoxic T-cell lymphocyte-4 mAb in the methods and conclusion sections of the abstract, in the introduction and in the legend for Figure 2. The sentences with the correct full name, anti-cytotoxic T-cell lymphocyte associated antigen-4 mAb, should have read as follows:

Abstract/Methods:

“Patients who received anti-PD-1/PD-L1 monotherapy or in combination with anti-cytotoxic T-cell lymphocyte **associated antigen-4** mAb were identified...”

Abstract/Conclusions:

“It is more common when anti-PD-1/PD-L1 mAbs are combined with anti-cytotoxic T-cell lymphocyte **associated antigen-4** mAb”

Introductions:

“... with durvalumab (PD-L1 mAb) and tremelimumab (cytotoxic T-cell lymphocyte **associated antigen-4** [CTLA-4] mAb.”

Legend of figure 2:

“versus in combination with anti-cytotoxic T-cell lymphocyte **associated antigen-4** monoclonal antibody.

The online version has been corrected in departure from the print. The authors apologize for the errors.

DOI: <https://doi.org/10.1200/JCO.2017.74.5042>; published August 1, 2017

The March 10, 2017, article by Guenancia, et al entitled “Reply to Z. Cheraghi et al” (J Clin Oncol 35:924-925) was published with an incorrect citation of a title in reference number 1.

The reference was given as:

1. Cheraghi Z, Ayubi E, Doosti-Irani A: Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: A systematic review and meta-analysis—methodological issues. J Clin Oncol 35:923, 2017

The reference should appear as:

1. Cheraghi Z, Ayubi E, Doosti-Irani A: Obesity as a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: Methodologic Issues to Avoid Misinterpretation in the Meta-Analysis. J Clin Oncol 35:923, 2017

The online version has been corrected in departure from the print. The authors apologize for the error.

DOI: <https://doi.org/10.1200/JCO.2017.74.5067>; published August 1, 2017